New Drug Reverses Gut Disease Tied to Aging Blood Cells

Scientists at Indiana University just uncovered why some people develop severe inflammatory bowel disease as they age, and they found a way to potentially reverse it with a pill.

The culprit is a sneaky blood condition called clonal hematopoiesis, or CHIP for short. It happens when blood stem cells pick up genetic mutations over time, and it's surprisingly common in older adults.

Researchers found that CHIP doesn't just sit quietly in the bloodstream. It "supercharges" inflammation in the gut, making Crohn's disease and ulcerative colitis far more severe.

The team analyzed health data from thousands of people in the UK Biobank and the NIH's All of Us Research Program. Women with CHIP and specific gene mutations faced significantly higher risks of developing Crohn's disease. Younger people with different mutations showed increased risk for ulcerative colitis.

Here's where it gets exciting. Using mouse models, the scientists pinpointed exactly how CHIP damages the colon. Then they tested a drug called APX3330 to block that pathway.

"Our most exciting discovery was that a single, oral drug that's already known to be safe in humans could reverse nearly all of the harmful effects," said lead researcher Dr. Ramesh Kumar. The drug reduced inflammation and restored colon health in their models.

The Bright Side

This discovery flips the script on CHIP. Scientists previously thought these age-related mutations were permanent and untreatable. Now it turns out their harmful effects might actually be reversible.

The drug offers something current IBD treatments can't: relief without weakening the immune system. Today's standard treatments often suppress the entire immune response, leaving patients vulnerable to infections.

Between 2.4 and 3.1 million Americans live with IBD, with the highest rates in adults 45 and older. Many face a lifetime of medications that come with serious side effects and don't always work.

Because CHIP contributes to inflammation in multiple conditions, this approach could extend beyond IBD. The research team plans to explore whether the drug might reduce inflammation in heart disease and kidney disease too.

The scientists are now preparing a Phase Ib clinical trial to test APX3330 in human IBD patients. The drug was developed by IU scientist Dr. Mark Kelley and has already passed safety testing.

For people struggling with chronic gut inflammation, this research offers something rare: a completely new angle of attack against an old problem that finally addresses the root cause instead of just managing symptoms.